187 related articles for article (PubMed ID: 20187091)
1. Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy.
Yu B; Douglas N; Ferin MJ; Nakhuda GS; Crew K; Lobo RA; Hershman DL
Cancer; 2010 May; 116(9):2099-105. PubMed ID: 20187091
[TBL] [Abstract][Full Text] [Related]
2. Incidence of chemotherapy-induced ovarian failure in premenopausal women undergoing chemotherapy for breast cancer.
Tiong V; Rozita AM; Taib NA; Yip CH; Ng CH
World J Surg; 2014 Sep; 38(9):2288-96. PubMed ID: 24700093
[TBL] [Abstract][Full Text] [Related]
3. Assessment of ovarian function after chemotherapy in women with early and locally advanced breast cancer from Serbia.
Malisic E; Susnjar S; Milovanovic J; Todorovic-Rakovic N; Kesic V
Arch Gynecol Obstet; 2018 Feb; 297(2):495-503. PubMed ID: 29101609
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy-Related Amenorrhea and Menopause in Young Chinese Breast Cancer Patients: Analysis on Incidence, Risk Factors and Serum Hormone Profiles.
Liem GS; Mo FK; Pang E; Suen JJ; Tang NL; Lee KM; Yip CH; Tam WH; Ng R; Koh J; Yip CC; Kong GW; Yeo W
PLoS One; 2015; 10(10):e0140842. PubMed ID: 26485568
[TBL] [Abstract][Full Text] [Related]
5. Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patients.
Su HC; Haunschild C; Chung K; Komrokian S; Boles S; Sammel MD; DeMichele A
Cancer; 2014 Dec; 120(23):3691-8. PubMed ID: 25081546
[TBL] [Abstract][Full Text] [Related]
6. Protective effect of goserelin on ovarian reserve during (neo)adjuvant chemotherapy in young breast cancer patients: a prospective cohort study in China.
Wang S; Pei L; Hu T; Jia M; Wang S
Hum Reprod; 2021 Mar; 36(4):976-986. PubMed ID: 33411897
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment anti-Mullerian hormone-based nomogram predicts menstruation status after chemotherapy for premenopausal women with hormone receptor-positive early breast cancer.
Xue C; Wei W; Sun P; Zheng W; Diao X; Xu F; Huang J; An X; Xia W; Hong R; Jiang K; Huang R; Yuan Z; Wang S; Li A; Zou R; Shi Y
Breast Cancer Res Treat; 2019 Feb; 173(3):619-628. PubMed ID: 30392113
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment serum anti-müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer.
Anderson RA; Cameron DA
J Clin Endocrinol Metab; 2011 May; 96(5):1336-43. PubMed ID: 21325458
[TBL] [Abstract][Full Text] [Related]
9. A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer.
Anders C; Marcom PK; Peterson B; Gu L; Unruhe S; Welch R; Lyons P; Behera M; Copland S; Kimmick G; Shaw H; Snyder S; Antenos M; Woodruff T; Blackwell K
Cancer Invest; 2008; 26(3):286-95. PubMed ID: 18317970
[TBL] [Abstract][Full Text] [Related]
10. Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors.
Su HI; Sammel MD; Green J; Velders L; Stankiewicz C; Matro J; Freeman EW; Gracia CR; DeMichele A
Cancer; 2010 Feb; 116(3):592-9. PubMed ID: 19918920
[TBL] [Abstract][Full Text] [Related]
11. Quantifying effect of combined oral contraceptive pill on functional ovarian reserve as measured by serum anti-Müllerian hormone and small antral follicle count using three-dimensional ultrasound.
Deb S; Campbell BK; Pincott-Allen C; Clewes JS; Cumberpatch G; Raine-Fenning NJ
Ultrasound Obstet Gynecol; 2012 May; 39(5):574-80. PubMed ID: 21997961
[TBL] [Abstract][Full Text] [Related]
12. Incidence and Predictive Factors for Recovery of Ovarian Function in Amenorrheic Women in Their 40s Treated With Letrozole.
Krekow LK; Hellerstedt BA; Collea RP; Papish S; Diggikar SM; Resta R; Vukelja SJ; Holmes FA; Reddy PK; Asmar L; Wang Y; Fox PS; Peck SR; O'Shaughnessy J
J Clin Oncol; 2016 May; 34(14):1594-600. PubMed ID: 26884554
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials.
Furlanetto J; Marmé F; Seiler S; Thode C; Untch M; Schmatloch S; Schneeweiss A; Bassy M; Fasching PA; Strik D; Stickeler E; Schem C; Karn T; Grischke EM; Denkert C; van Mackelenbergh M; Müller V; Nekljudova V; Loibl S
Eur J Cancer; 2021 Jul; 152():193-203. PubMed ID: 34116270
[TBL] [Abstract][Full Text] [Related]
14. Feature of amenorrhea in postoperative tamoxifen users with breast cancer.
Kim H; Han W; Ku SY; Suh CS; Kim SH; Choi YM
J Gynecol Oncol; 2017 Mar; 28(2):e10. PubMed ID: 27894163
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Anti-Mullerian Hormone Levels, Antral Follicle Counts, and Mean Ovarian Volumes in Chemotherapy-Induced Amenorrhea among Breast Cancer Patients: A Prospective Clinical Study.
Ünal Ç; Ordu Ç; Özmen T; İlgun AS; Çelebi F; Baysal B; Özkurt E; Duymaz T; Erdoğan İyigün Z; Kurt S; Öztürk MA; Pilancı KN; Alço G; Yararbaş K; Kayan Tapan T; Güven DC; Soybir G; Özmen V
Curr Oncol; 2023 Oct; 30(10):9217-9229. PubMed ID: 37887566
[TBL] [Abstract][Full Text] [Related]
16. Association Between Biomarkers of Ovarian Reserve and Infertility Among Older Women of Reproductive Age.
Steiner AZ; Pritchard D; Stanczyk FZ; Kesner JS; Meadows JW; Herring AH; Baird DD
JAMA; 2017 Oct; 318(14):1367-1376. PubMed ID: 29049585
[TBL] [Abstract][Full Text] [Related]
17. Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol.
Hazout A; Bouchard P; Seifer DB; Aussage P; Junca AM; Cohen-Bacrie P
Fertil Steril; 2004 Nov; 82(5):1323-9. PubMed ID: 15533354
[TBL] [Abstract][Full Text] [Related]
18. Anti-Müllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy - A translational research project of the SUCCESS A study.
Trapp E; Steidl J; Rack B; Kupka MS; Andergassen U; Jückstock J; Kurt A; Vilsmaier T; de Gregorio A; de Gregorio N; Tzschaschel M; Lato C; Polasik A; Tesch H; Schneeweiss A; Beckmann MW; Fasching PA; Janni W; Müller V
Breast; 2017 Oct; 35():130-135. PubMed ID: 28732324
[TBL] [Abstract][Full Text] [Related]
19. Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients.
Bozza C; Puglisi F; Lambertini M; Osa EO; Manno M; Del Mastro L
Endocr Relat Cancer; 2014 Feb; 21(1):R51-65. PubMed ID: 24292601
[TBL] [Abstract][Full Text] [Related]
20. Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen.
Ravdin PM; Fritz NF; Tormey DC; Jordan VC
Cancer Res; 1988 Feb; 48(4):1026-9. PubMed ID: 3123050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]